EUCTR2006-000297-72-GB进行中（未招募）1 期
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mg
BEAUFOUR IPSEN Pharma0 个研究点目标入组 125 人开始时间: 2012年2月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •At the screening visit:
- •Provision of written informed consent prior to any study related procedures.
- •Male or female aged between 18 and 75 years inclusive.
- •The patient must have had documentation supporting the diagnosis of acromegaly, including elevated GH and/or IGF-1 levels.
- •The patient is treated with pegvisomant, because of IGF-1 level remaining above ULN when treated with somatostatin analogue, on a daily basis for at least 3 months and has normal (age and sex adjusted) IGF-1 levels, or IGF-1 level above ULN after treatment with pegvisomant 30 mg per day,
- •OR the patient is treated with lanreotide Autogel or octreotide LAR for at least 6 months including the last 3 months at the highest marketed dose, and has a serum IGF-1 level above ULN, 28 days after the last injection.
- •At the end of the run-in period:
- •The patient has a serum IGF-1 level above 1.2 x ULN, or a serum IGF-1 level between ULN and a 1.2 x ULN and a serum GH nadir > 1 µg/L ( assessed by an OGTT), 28 days after the 3rd injection of lanreotide Autogel 120 mg.
- •The patient is diabetic and has a serum IGF-1 level above 1.2 x ULN, 28 days after the 3rd injection of lanreotide Autogel 120 mg.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The patient has undergone pituitary surgery or raditherapy within 6 months prior to study entry.
- •It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study.
- •The patient has a history of hypersensitivity to lanreotide or pegvisomant or drugs with a similar chemical structure.
- •The patient has already been treated with a somatostatin analogue associated with a GH antagonist.
- •The patient has received a dopamine agonist within 6 weeks prior to study entry.
- •The patient has been treated with any unlicensed drug within the last 30 days before study entry.
- •The patient is likely to require treatment during the study with drugs that are not permitted by the study protocol.
- •The patient has abnormal hepatic function at study entry (defined as AST, ALT, GGT, alkaline phosphatase, prothrombin time or total bilirubin above 2 ULN).
- •The patient is at risk of pregnancy or is lactating. Females of childbearing potential must provide a negative pregnancy test within 5 days before the start of the study and must be using oral, double barrier or injectable contraception. Non childbearing potential is defined as post-menopause for at least one year, surgical sterilisation or hysterectomy at least three months before the start of the study.
- •The patient has a history of, or known current, problems with alcohol or drug abuse.
- •The patient has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
- •The patient has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardise the subject’s safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.
研究者
相似试验
进行中（未招募）
不适用
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgAcromegalyMedDRA version: 8.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2006-000297-72-SEBEAUFOUR IPSEN Pharma68
进行中（未招募）
1 期
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgMedDRA version: 8.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2006-000297-72-GRBEAUFOUR IPSEN Pharma125
进行中（未招募）
不适用
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgAcromegalyEUCTR2006-000297-72-CZBEAUFOUR IPSEN Pharma68
已完成
3 期
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgGigantism10021112AcromegalyNL-OMON30806Ipsen Pharmaceuticals20
进行中（未招募）
不适用
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mg aloneAcromegalyMedDRA version: 8.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2006-000297-72-DEBEAUFOUR IPSEN Pharma68